Results 61 to 70 of about 12,380 (194)

Pharmacokinetic Interaction Between Prasugrel and Ritonavir in Healthy Volunteers

, 2012
: The new anti-aggregating agent prasugrel is bioactivated by cytochromes P450 (CYP) 3A and 2B6. Ritonavir is a potent CYP3A inhibitor and was shown in vitro as a CYP2B6 inhibitor.
Pierre Dayer, Virginie Ancrenaz, Dayer, Pierre, Samer, Caroline Flora, Caroline Samer, Youssef Daali, Staub, Christian Olivier, Christian Staub, Jules Desmeules, Daali, Youssef, Desmeules, Jules Alexandre, Julien Déglon, Ancrenaz, Virginie, Deglon, Julien   +13 more
core   +1 more source

Single antiplatelet therapy with use of prasugrel in patients undergoing percutaneous coronary intervention.

, 2021
OBJECTIVES We aimed to assess the ischemic and bleeding risks of single antiplatelet therapy (SAPT) with prasugrel compared with standard dual antiplatelet therapy (DAPT) (aspirin plus clopidogrel for 1 year) in patients with chronic coronary syndrome
Heg, Dik, Windecker, Stephan, Lorenz Räber, Thomas Pilgrim, Otsuka, Tatsuhiko, Thomas Zanchin, Bernhard Meier, Raminta Kavaliauskaite, Sarah Bär, Stortecky, Stefan, Tatsuhiko Otsuka, Yasushi Ueki, Bär, Sarah, Marco Valgimigli, Zanchin, Thomas, Stephan Windecker, Räber, Lorenz, Dik Heg, Pilgrim, Thomas, Ueki, Yasushi, Kavaliauskaite, Raminta, Valgimigli, Marco, Meier, Bernhard, Stefan Stortecky   +23 more
core   +1 more source

P2Y₁₂ Receptor Inhibitors in the Treatment of Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention: Possibilities of Prasugrel

Рациональная фармакотерапия в кардиологии, 2019
The possibilities of P2Y12 receptor inhibitors application in the treatment of patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) are discussed in the article.
N. M. Vorobyeva
doaj   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1547-1554, June 2026.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon, Chen Gurevitz, Tzippy Shochat, Shiri Kushnir, Guy Witberg, Amos Levi, Dan Gilon, Ran Kornowski, Paaladinesh Thavendiranathan, Husam Abdel Qadir, Zaza Iakobishvili   +10 more
wiley   +1 more source

Absence of differential effect of ticagrelor versus prasugrel maintenance dose on endothelial function in patients with stable coronary artery disease

Hellenic Journal of Cardiology, 2018
Background: Endothelial function may be improved by ticagrelor through adenosine-mediated mechanisms. We aimed to assess the effect of ticagrelor versus prasugrel on endothelial function in patients with stable coronary artery disease (CAD).
Ioanna Xanthopoulou, Ilianna Bei, Theodora Bampouri, Nikolaos Barampoutis, Athanasios Moulias, Periklis Davlouros, Dimitrios Alexopoulos   +6 more
doaj   +1 more source

Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment-Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel [PDF]

, 2019
BACKGROUND: Despite successful restoration of epicardial vessel patency with primary percutaneous coronary intervention, coronary microvascular injury occurs in a large proportion of patients with ST-segment-elevation myocardial infarction, adversely ...
de Waard, Guus A., van der Hoeven, Nina W., Escaned, Javier, Nap, Alexander, ten Cate, Tim J. F., Diletti, Roberto, van Rossum, Albert C., Ten Cate, Tim J F, van Leeuwen, Maarten A. H., Piek, Jan J., Riksen, Niels P., Riksen, Niels P, van de Ven, Peter M, Lemkes, Jorrit S., Janssens, Gladys N., Lemkes, Jorrit S, Everaars, Henk, van de Ven, Peter M., Nijveldt, Robin, van Royen, Niels, Piek, Jan J, van Rossum, Albert C, van der Hoeven, Nina W, de Waard, Guus A, van Mieghem, Nicolas M., Van Mieghem, Nicolas M, von Birgelen, Clemens, Janssens, Gladys N, Valgimigli, Marco, van Leeuwen, Maarten A H   +29 more
core   +1 more source

Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE‐ACS) Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundProton pump inhibitors (PPIs) reduce gastrointestinal bleeding events but may alter clopidogrel metabolism. We sought to understand the comparative effectiveness and safety of prasugrel versus clopidogrel in the context of proton pump inhibitor
Larry R. Jackson, Eric D. Peterson, Lisa A. McCoy, Christine Ju, Marjorie Zettler, Brian A. Baker, John C. Messenger, Douglas E. Faries, Mark B. Effron, David J. Cohen, Tracy Y. Wang   +10 more
doaj   +1 more source

CYP2C19 Polymorphism and Platelet Aggregation‐Associated Risks in Atrial Fibrillation Patients Undergoing PCI

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT CYP2C19 genetic polymorphisms impact the antiplatelet effect of clopidogrel and associate with ischemic and bleeding risk in patients undergoing percutaneous coronary intervention (PCI). This study aimed to evaluate the association of CYP2C19 and platelet reactivity (PR) with these risks, in atrial fibrillation (AF) patients undergoing PCI ...
Diona Gjermeni, Sofia Szabó, Viktoria Anfang, Hannah Vetter, Carina Juelch, Svenja Rademacher, Tian Li, Stefan Leggewie, David Hesselbarth, Daniel Duerschmied, Dietmar Trenk, Dirk Westermann, Christoph B. Olivier   +12 more
wiley   +1 more source

The development of type 2 diabetes amongst sibling pairs in the South‐South region of Nigeria: The effect of genetics, environment and lifestyle

Diabetic Medicine, Volume 43, Issue 6, June 2026.
Abstract Introduction Type 2 diabetes is a complex condition with a multifactorial pathogenesis. The pathogenesis is considered to be polygenic due to complex interactions between genetic/epigenetic and environmental factors. The aim of this study is to determine the genetic, environmental and lifestyle factors associated with the development of type 2
Sunny Chinenye, Ibi Erekosima, Adrian H. Heald, Gesiye Bozimo, Simon G. Anderson, Samuel Seidu, Kariba Akhidue, Adaeze Ugwu, Chioma Unachukwu, Ibitrokoemi Korubo, Kingsley Chukwuemeka Patrick‐Iwuanyanwu, Victoria Gomba, Uwoma Batubo, Victoria Akanatei, Victor Ken‐Uba, Iyeopu Siminialayi, Sokiprim Akoko, Justin Ideozu, Hamilton Opurum   +18 more
wiley   +1 more source

PHARMACODYNAMIC EFFECTS OF PRASUGREL DOSING REGIMENS IN PATIENTS ON MAINTENANCE PRASUGREL THERAPY: RESULTS OF A PROSPECTIVE RANDOMIZED STUDY

, 2012
ObjectivesThe purpose of this study is to assess the pharmacodynamic effects of different prasugrel dosing regimens in patients on maintenance prasugrel therapy.BackgroundThere are a growing number of patients on chronic prasugrel therapy regimens ...
Tomasello, Salvatore, Charlton, Ronald K., Box, Lyndon C., Box, Lyndon, Seecheran, Naveen, Ueno, Masafumi, Kodali, Murali, Guzman, Luis A., Angiolillo, Dominick, Angiolillo, Dominick J., Zenni, Martin M., Bass, Theodore A., Ferreiro, Jose Luìs, Zenni, Martin, Bass, Theodore, Desai, Bhaloo, Tomasello, Salvatore D., Rollini, Fabiana, Tello-Montoliu, Antonio, Guzman, Luis, Ferreiro, José Luis   +20 more
core   +1 more source